Single-cell multiomics identifies an ALDH9A1–carnitine signaling axis driving resistance of NSCLC to immunotherapy
Proceedings of the National Academy of Sciences · 18.08.2026 · 123 (33)
DOI: 10.1073/pnas.2535328123 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, online erschienen am 10.08.2026. Verfasst von Hailei Du und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200025, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Carnitine, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Immunotherapy resistance remains a major barrier to achieving sustained patient improvement in non–small cell lung cancer (NSCLCs). Here, through integrating CODEX, metabolomics, CyTOF, ATAC-seq, and single-cell spatial transcriptomics from NSCLC tumors, we uncover an unrecognized role of ALDH9A1 in promoting resistance to anti-PD-1 therapy. In immunocompetent, but not immunocompromised mouse models, loss of ALDH9A1 markedly restrains tumor growth. This effect is accompanied by increased maturation of tertiary lymphoid structures and reduced accumulation of protumorigenic MDSCs within tumor immune microenvironment. Mechanistically, ALDH9A1-driven carnitine production elevates acetyl-CoA levels, remodels chromatin accessibility, and activates Il1b superenhancers in tumor cells, thereby promoting MDSC polarization and CD8 + T cell exhaustion. In vivo, genetic or pharmacological inhibition of ALDH9A1, or antibody-mediated IL-1β neutralization, suppresses tumor progression and restores sensitivity to anti-PD-1 therapy. IL-1β further activates NF-κB and upregulates ALDH9A1, establishing a feedback ALDH9A1-IL-1β loop. Importantly, the ALDH9A1/IL-1β axis is frequently hyperactivated in NSCLC patients and correlates with inferior responses to anti-PD-1 immunotherapy. Together, this study reveals a previously unappreciated NSCLC-specific immunoregulatory pathway and identifies ALDH9A1 as a promising therapeutic target for improving immunotherapy efficacy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Thoracic Surgery, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200025, China.
- Department of Respiratory and Critical Care Medicine, Weifang Second People's Hospital, Weifang 261041, Shandong, China.
- Department of Intensive Care Medicine, The First Affiliated Hospital of University of Science and Technology of China, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230031,…
- Department of Intensive Care Medicine, Anhui Provincial Cancer Hospital, Hefei 230031, Anhui, China.
- Department of Interventional Therapy, The First Hospital of Jilin University, Changchun 130012, Jilin, China.
- Department of Public Laboratory Platform, The First Hospital of Jilin University, Changchun 130012, Jilin, China.
ORCID-Profile: Hailei Du, Tong Lang, Xiaoxue Zha, Chao Qu, Ling Chen, Shihua Yao, Xing Feng, Zhaohui Jin
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Du, H., Lang, T., Zha, X., Qu, C., Chen, L., Yao, S., Feng, X., & Jin, Z. (2026). Single-cell multiomics identifies an ALDH9A1–carnitine signaling axis driving resistance of NSCLC to immunotherapy. Proceedings of the National Academy of Sciences, 123(33). https://doi.org/10.1073/pnas.2535328123
Vancouver
Du H, Lang T, Zha X, Qu C, Chen L, Yao S, et al. Single-cell multiomics identifies an ALDH9A1–carnitine signaling axis driving resistance of NSCLC to immunotherapy. Proceedings of the National Academy of Sciences. 2026;123(33). doi:10.1073/pnas.2535328123
BibTeX
@article{Du2026,
author = {Du, Hailei and Lang, Tong and Zha, Xiaoxue and Qu, Chao and Chen, Ling and Yao, Shihua and Feng, Xing and Jin, Zhaohui},
title = {Single-cell multiomics identifies an ALDH9A1–carnitine signaling axis driving resistance of NSCLC to immunotherapy},
journal = {Proceedings of the National Academy of Sciences},
year = {2026},
volume = {123},
number = {33},
doi = {10.1073/pnas.2535328123}
}
EUVIMED